NCT05401630
Mental Stress Reactivity in Women With CMD
At risk: Primary completion moved at least 2 years 2 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 7 versions: 5 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary and study completion dates pushed to Dec 2028 Show 4 more changesShow less
- Eligibility criteria expanded, about 92 words
- Secondary endpoints: details revised at 3 of 3 entries
- Study description revised
- Site details revised at 1 of 4 sites
- Notable Eligibility criteria expanded, about 4 words
- Secondary endpoints: details revised at 1 of 3 entries
- Study description revised
- Notable Phase: Not specified to Not applicable
- Primary completion date: Jun 2027 to Sep 30, 2026
- Study completion date: Dec 2027 to Dec 31, 2026
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jun 2022 to Jul 19, 2022
- Site details revised at 4 of 4 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Symptomatic women with chest pain and no obstructive CAD who have an abnormal myocardial flow reserve (MFR \< 2.5)
This group will serve as one comparison group since these women represent the prevailing paradigm of ischemia from obstructive stenosis while sharing common cardiovascular risk factors with the CMD group.
Asymptomatic control women with no prior history of CAD or angina, who are age-matched to the CMD women; not on any cardiac medications, who will also have to pass a maximal Bruce protocol exercise treadmill test.
Other: Study Procedures
Sites
4 sites in 1 country